Skip to main content
NCBI home page
British Medical Journal logoLink to British Medical Journal
. 1978 Sep 16;2(6140):791–793. doi: 10.1136/bmj.2.6140.791

Refractory acute leukaemia in adults treated with sequential colaspase and high-dose methotrexate

Boh-Seng Yap, Kenneth B McCredie, Robert S Benjamin, Gerald P Bodey, Emil J Freireich
PMCID: PMC1607847  PMID: 279387

Abstract

Thirty-nine adults with acute leukaemia who had relapsed when receiving extensive chemotherapy were treated with a combination of methotrexate and colaspase (L-asparaginase) given sequentially. Patients initially received 50-80 mg/m2 methotrexate, followed three hours later by intravenous colaspase, 40 000 IU/m2. Seven days later intravenous methotrexate, 120 mg/m2 was given. Each dose of methotrexate was followed 24 hours later by colaspase, and the two-day course of treatment was repeated every 7-14 days. The methotrexate dose was increased to tolerance by increments of 40 mg/m2 with each course, while the colaspase dose remained constant unless abnormal liver function developed, when it was reduced by half.

Overall, 18 out of 39 patients achieved complete remission (46%). Of these, 13 out of 21 (62%) had acute lymphoblastic leukaemia, three out of seven (43%) acute undifferentiated leukaemia, and two out of 11 (18%) acute myeloblastic leukaemia. The median duration of complete remission was 20 weeks and the median duration of survival in complete responders was 45 weeks. The median number of courses needed to achieve complete remission was three. The maximum tolerated dose of methotrexate was 400 mg/m2 (median 200 mg/m2). Major side effects were due to colaspase. Methotrexate in doses of up to 400 mg/m2 caused minimal myelosuppression and stomatitis, which suggested that colaspase given sequentially provides relative protection from methotrexate toxicity without the need for folinic acid (citrovorum factor) rescue.

The combination of sequential colaspase and methotrexate is highly effective in reinducing remission in patients with acute lymphoblastic leukaemia or acute undifferentiated leukaemia. The regimen is easy to administer and relatively non-toxic, so it is suitable for use in outpatients, either alone or combined with other agents.

Full text

PDF
791

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodey G. P., Hewlett J. S., Coltman C. A., Jr, Rodriguez V., Freireich E. J. Therapy of adult acute leukemia with daunorubicin and L-asparaginase. Cancer. 1974 Mar;33(3):626–630. doi: 10.1002/1097-0142(197403)33:3<626::aid-cncr2820330306>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  2. Chlopkiewicz B., Koziorowska J. Role of amino acid depletion in combined treatment of neoplastic cells with methotrexate and L-asparaginase. Cancer Res. 1975 Jun;35(6):1524–1529. [PubMed] [Google Scholar]
  3. Connors T. A., Jones M. Antagonism of the anti-tumour effects of asparaginase by methotrexate. Biochem Pharmacol. 1970 Nov;19(11):2927–2931. doi: 10.1016/0006-2952(70)90033-x. [DOI] [PubMed] [Google Scholar]
  4. GEHAN E. A. A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. Biometrika. 1965 Jun;52:203–223. [PubMed] [Google Scholar]
  5. Gahrton G., Engstedt L., Franzén S., Gullbring B., Holm G., Höglund S., Killander A., Killander D., Lockner D., Mellstedt H. Induction of remission with l-Asparaginase, cyclophosphamide, cytosine arabinoside, and prednisolone in adult patients with acute leukemia. Cancer. 1974 Aug;34(2):472–479. doi: 10.1002/1097-0142(197408)34:2<472::aid-cncr2820340236>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  6. Gottlieb J. A., Serpick A. A. Prolonged intravenous methotrexate therapy in the treatment of acute leukemia and solid tumors. Cancer Res. 1970 Aug;30(8):2132–2138. [PubMed] [Google Scholar]
  7. Hryniuk W. M., Bertino J. R. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest. 1969 Nov;48(11):2140–2155. doi: 10.1172/JCI106181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lister T. A., Whitehouse J. M., Beard M. E., Brearley R. L., Wrigley P. F., Oliver R. T., Freeman J. E., Woodruff R. K., Malpas J. S., Paxton A. M. Combination chemotherapy for acute lymphoblastic leukaemia in adults. Br Med J. 1978 Jan 28;1(6107):199–203. doi: 10.1136/bmj.1.6107.199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Rodriguez V., Hart J. S., Freireich E. J., Bodey G. P., McCredie K. B., Whitecar J. P., Jr, Coltman C. A., Jr Pomp combination chemotherapy of adult acute leukemia. Cancer. 1973 Jul;32(1):69–75. doi: 10.1002/1097-0142(197307)32:1<69::aid-cncr2820320109>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  10. Vadlamudi S., Krishna B., Reddy V. V., Goldin A. Schedule-dependent therapeutic synergism for L-asparaginase and methotrexate in leukemic (L5178Y) mice. Cancer Res. 1973 Sep;33(9):2014–2019. [PubMed] [Google Scholar]
  11. Vogler W. R., Jacobs J. Toxic and therapeutic effects of methotrexate-folinic acid (Leucovorin) in advanced cancer and leukemia. Cancer. 1971 Oct;28(4):894–901. doi: 10.1002/1097-0142(1971)28:4<894::aid-cncr2820280412>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES